| [1] |
Ryu SW, Ho K, O'Toole SA, et al. Case report of male breast cancer detected on magnetic resonance imaging[J]. J Med Imaging Radiat Oncol, 2017, 61(3): 369-371.
|
| [2] |
Feifei Zhou, Rong Huang, Jun Jiang, et al. A meta-analysis based on case-control studies shows the similar prognosis between male and female patients with breast cancer[J]. Chinese-German J Clin Oncol, 2011, 10(6): 311-316.
|
| [3] |
Chavez-Macgregor M, Clarke CA, Lichtensztajn D, et al. Male breast cancer according to tumor subtype and race: a population-based study[J]. Cancer, 2013, 119(9): 1611-1167.
|
| [4] |
Cutuli B, Le-Nir CC, Serin D, et al. Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases[J]. Crit Rev Oncol Hematol, 2010, 73(3): 246-254.
|
| [5] |
Massarweh SA, Choi GL. Special considerations in the evaluation and management of breast cancer in men[J]. Curr Probl Cancer, 2016, 40(2-4): 163-171.
|
| [6] |
Shaaban AM, Ball GR, Brannan RA, et al. A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences[J]. Breast Cancer Res Treat, 2012, 133(3): 949-958.
|
| [7] |
Muir D, Kanthan R, Kanthan SC. Male versus female breast cancers. A population-based comparative immunohistochemical analysis[J]. Arch Pathol Lab Med, 2003, 127(1): 36-41.
|
| [8] |
Shandiz FH, Tavassoli A, Sharifi N, et al. Hormone receptor expression and clinicopathologic features in male and female breast cancer[J]. Asian Pac J Cancer Prev, 2015, 16(2): 471-474.
|
| [9] |
Humphries MP, Rajan SS, Honarpisheh H, et al. Characterisation of male breast cancer: a descriptive biomarker study from a large patient series[J]. Sci Rep, 2017, 7: 45293.
|
| [10] |
Kidwai N, Gong Y, Sun X, et al. Expression of androgen receptor and prostate-specific antigen in male breast carcinoma[J]. Breast Cancer Res, 2004, 6(1): R18-23.
|
| [11] |
Kwiatkowska E, Teresiak M, Filas V, et al. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients[J]. Clin Cancer Res, 2003, 9(12): 4452-4459.
|
| [12] |
Cardoso F, Bartlett JMS, Slaets L, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program[J]. Ann Oncol, 2018, 29(2): 405-417.
|
| [13] |
Ni M, Chen Y, Lim E, et al. Targeting androgen receptor in estrogen receptor-negative breast cancer[J]. Cancer Cell, 2011, 20(1): 119-131.
|
| [14] |
O'Shaughnessy J, Campone M, Brain E, et al. Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer[J]. Ann Oncol, 2016, 27(1): 106-113.
|
| [15] |
Bloom KJ, Govil H, Gattuso P, et al. Status of HER-2 in male and female breast carcinoma[J]. Am J Surg, 2001, 182(4): 389-392.
|
| [16] |
Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J]. Proc Natl Acad Sci U. S. A, 2001, 98(19): 10869-10874.
|
| [17] |
Kornegoor R, Verschuur-Maes AHJ, Buerger H, et al. Immunophenotyping of male breast cancer[J]. Histopathology, 2012, 61(6): 1145-1155.
|
| [18] |
Nilsson C, Johansson I, Ahlin C, et al. Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact[J]. Acta Oncol, 2013, 52(1): 102-109.
|
| [19] |
Abreu MH, Afonso N, Abreu PH, et al. Male breast cancer:looking for better prognostic subgroups[J]. Breast, 2016, 26: 18-24.
|
| [20] |
Schildhaus HU, Schroeder L, Merkelbach-Bruse S, et al. Therapeutic strategies in male breast cancer: clinical implications of chromosome 17 gene alterations and molecular subtypes[J]. Breast, 2013, 22(6): 1066-1071.
|
| [21] |
Basham VM, Lipscombe JM, Ward JM, et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer[J]. Breast Cancer Res, 2002, 4(1): R2.
|
| [22] |
Thompson D, Easton D, Breast Cancer Linkage Consortium.Variation in cancer risks, by mutation position, in BRCA2 mutation carriers[J]. Am J Hum Genet, 2001, 68(2): 410-419.
|
| [23] |
Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci[J]. Nature, 2007, 447(7148): 1087-1093.
|
| [24] |
Orr N, Cooke R, Jones M, et al. Genetic variants at chromosomes 2q35, 5p12, 6q25.1,10q26.13, and 16q12.1 influence the risk of breast cancer in men[J]. PLoS Genet, 2011, 7(9): e1002290..
|
| [25] |
Johansson I, Nilsson C, Berglund P, et al. High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer[J]. Breast Cancer Res Treat, 2011, 129(3): 747-760.
|
| [26] |
Piscuoglio S, Ng CK, Murray MP, et al. The genomic landscape of male breast cancer[J]. Clin Cancer Res, 2016, 22(16): 4045-4056.
|
| [27] |
Lehmann U, Streichert T, Otto B, et al. Identification of differentially expressed microRNAs in male breast cancer[J]. BMC Cancer, 2010, 10: 109.
|
| [28] |
Fassan M, Baffa R, Palazzo JP, et al. MicroRNA expression profiling of male breast cancer[J]. Breast Cancer Res, 2009, 11(4): R58.
|
| [29] |
Pinto R, Pilato B, Ottini L, et al. Different methylation and microRNA expression pattern in male and female familial breast cancer[J]. J Cell Physiol, 2013, 228(6): 1264-1269.
|
| [30] |
Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer[J]. N Engl J Med, 2004, 351(27): 2817-2826.
|
| [31] |
Kiluk JV, Lee MC, Park CK, et al. Male breast cancer: management and follow-up recommendations[J]. Breast J, 2011, 17(5): 503-509.
|
| [32] |
Grenader T, Yerushalmi R, Tokar M, et al. The 21-gene recurrence score assay (Oncotype DX™) in estrogen receptor-positive male breast cancer: experience in an Israeli cohort[J]. Oncology, 2014, 87(1): 1-6.
|
| [33] |
Humphries MP, Sundara Rajan S, Droop A, et al. A case-matched gender comparison transcriptomic screen identifies eIF4E and eIF5 as potential prognostic markers in male breast cancer[J]. Clin Cancer Res, 2017, 23(10): 2575-2583.
|